Overview

Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg20IU/ml or HBsAg Negative Without Serological Conversion

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the immunogenicity and safety of TVAX-008 injection in antiviral untreated/untreated chronic hepatitis B patients with HBsAg20 IU/mL, or HBsAg negative and no seroconversion through an investigator-initiated clinical study.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Grand Theravac Life Sciences (Nanjing) Co., Ltd.